** Drug developer's shares down 20 pct after IPOcarries over into this week
** Stock opens at $8.50, well below $10 IPO price, anddescends immediately to as low as $7.56
** Company redistributed revised prospectus yesterday forsale of 5.5 mln shares at $10, significantly below original$13-$15 range
** Existing holders indicate interest for up to $25 mln ofcommon shares in revised offering
** CLCD to use proceeds to fund Phase 3 clinical trials oftop drug candidate lasmiditan to treat migraine patients withhigh cardiovascular risk factors
** Deal prices in potentially busiest week YTD for newissues as 12 companies, including 8 biotechs, seek nearly $2 blnof capital
** Even highly touted Adaptimmune Therapeutics PLC sees it shares drop below issue after cancer drug company pricesupsized offering at top of filed range
(RM: lance.tupper.thomsonreuters.com@reuters.net)